Two secondary mechanisms have been recognized as being associated with ALK inhibitor resistance: the first one related to mutations in the ALK kinase domain impairing ALK protein binding; and the second as a consequence of secondary mutations in the MAPK signaling pathway, achieving ALK independence, resembling what has been reported for other ALK-expressing neoplasms [108,109]. This evidence concerns the gene ALK and neoplasm.